drugset / Trial / NCT07305987
PRO-232 in Patients Subjected to Cataract Surgery
RandomizedParallel-groupDouble-blindTreatment
Summary
The main objective of this study is to evaluate the efficacy and safety of the PRO-232 formulation manufactured by Laboratorios Sophia S.A. de C.V. on the ocular surface of postoperative cataract patients versus a concomitant administration of ophthalmic moxifloxacin and dexamethasone.
Timeline
- Start
- 2025-10-27
- Primary completion
- 2026-06-30
- Completion
- 2026-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dexamethasone | Small molecule | 0.1 % | Topical |
| Comparator | Moxifloxacin | Small molecule | 0.5 % | Topical |
| Subject | PRO-232 | Unknown | — | Topical |